Repurposed metformin–apigenin combination therapy for metabolic dysfunction-associated steatohepatitis: from integrative multi-omics discovery to in vivo validation
Kanglong Zhang, Yihua Chen, Linwei Ran, Weizhao Tong, Lu Dai, Zhen Yang, Qi Chen, Jie Zheng, Guoxin Hu · 2026
Read Repurposed metformin–apigenin combination therapy for metabolic dysfunction-associated steatohepatitis: from integrative multi-omics discovery to in vivo validation by Kanglong Zhang, Yihua Chen, Linwei Ran, Weizhao Tong, Lu Dai, Zhen Yang, Qi Chen, Jie Zheng, Guoxin Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13586655.txt.
Description
Kanglong Zhang and co-authors search for a combined drug treatment in a 2026 study of fatty liver disease. The target illness is metabolic dysfunction-associated steatohepatitis, a severe form of liver disease. Single drugs often fall short because the disease has many drivers.
The team combined RNA sequencing, lipid profiling, and network methods in mouse liver tissue. Human liver samples and Mendelian randomization helped test which signals matter for people. That search led to a repurposed pairing of metformin with apigenin. Tests in living animals then checked the pairing. The study offers a route from large-scale data to a reasoned two-drug plan for this disease.
Catalog record
| CREATOR | Kanglong Zhang, Yihua Chen, Linwei Ran, Weizhao Tong, Lu Dai, Zhen Yang, Qi Chen, Jie Zheng, Guoxin Hu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |